News & events - Mendus

News & events
<picture><source type="image/webp" srcSet="/static/bd6d2c42e99d69343f6fd727c3137fdd/18e05/Image.webp 740w,/static/bd6d2c42e99d69343f6fd727c3137fdd/81bef/Image.webp 1480w,/static/bd6d2c42e99d69343f6fd727c3137fdd/2d0b8/Image.webp 2960w" sizes="(min-width: 2960px) 2960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2960px) 2960px, 100vw" decoding="async" loading="lazy" src="/static/bd6d2c42e99d69343f6fd727c3137fdd/c9eb6/Image.jpg" srcSet="/static/bd6d2c42e99d69343f6fd727c3137fdd/bbd3f/Image.jpg 740w,/static/bd6d2c42e99d69343f6fd727c3137fdd/087e6/Image.jpg 1480w,/static/bd6d2c42e99d69343f6fd727c3137fdd/c9eb6/Image.jpg 2960w" alt="&lt;p&gt;Image of a middle aged man dressed in a blazer, clapping his hands while smiling.&lt;/p&gt;
"/></picture>

Press Releases
No articles found

Events
21 August 2025
Previous
Q2 2025 financial report and business updateLive audiocast 14:00  CET August 21, 2025  
More details
May 2025Previous
Q1 2025 financial report and business update
Live audiocast 13:30  CET May 6, 2025  
More details
February 2025Previous
Year-end Report Q4 2024 and business update
Live audiocast 08:30  CET February 13, 2025  
More details
November 2024Previous
Third quarter 2024 financial report and business update
Live audiocast 14:00 CET November 8, 2024  
More details
October 2024Previous
Mendus CEO Erik Manting presented at the LSX Nordic Congress 2024 held on October 9, 2024
More details
September 2024Previous
Mendus CEO Erik Manting presented at the H.C. Wainwright 26th Annual Global Investment Conference held on September 9, 2024
More details
August 2024Previous
Second quarter 2024 financial report and business update
Live audiocast 10:00 CEST August 23, 2024  
More details

Interviews
19 December 2024
Analyst interview – EdisonCEO Erik Manting talks about the recent progress in developing Mendus’ lead product vididencel as an active immunotherapy for acute myeloid leukemia and additional indications, in an interview with Edison analyst Arron Aatkar,
Watch
December 2024
Analyst interview – Redeye
CEO Erik Manting speaks with Redeye analyst Christian Binder about the positive survival update of the ADVANCE II Phase 2 trial with vididencel in AML and other abstracts presented at ASH24 
Watch
December 2024
Investor Update – Investor Studios
CEO Erik Manting talks about the latest data of the ADVANCE II Phase 2 trial presented at ASH 2024, demonstrating durable survival of AML patients treated with Mendus lead product vididencel.
Watch
December 2024
Redeye Technology & Life Science Day
CEO Erik Manting presents at Redeye Technology & Life Science Day 2024 – December 3
Watch
November 2024
Biotech TV – BioEurope
CEO Erik Manting talks about immunotherapy in AML in an interview with Biotech TV at BIO-Europe
Watch
August 2024
Analyst interview – Edison
August 23

CEO Erik Manting talks about the company’s exciting recent developments and future plans in an interview with Edison's Soo Romanoff
Watch
June 2024
Analyst interview – Redeye
CEO Erik Manting talks about the latest data presented at EHA demonstrating the link between functional immune responses and long-term survival in AML patients treated with Mendus lead product vididencel
Watch

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi-1818292058-ebXR4TNaj7R49jJGs4noeE:before { opacity: 1; background-image: url('/static/9374a44515aa9e27ec32f6b9282ea2f7/d3468/NewsEvents_2_mobile.jpg'); }

Investors